Ultrasonic tumor permeabilization: Enhancing chemotherapy delivery in solid cancers

Dear Editor, Chemotherapy remains ineffective against solid tumors due to their dense extracellular matrix, abnormal vasculature, and high interstitial pressure coalesce to create a barrier to drug penetration and distribution. This challenge is even particularly pronounced in pancreatic and brain tumors, where chemotherapy response rates remain dismal. The advent of ultrasonic tumor permeabilization using focused ultrasound and microbubble technology represents a significant breakthrough in research on overcoming drug resistance in solid tumors toward overcoming these barriers and improving outcomes.[1] Ultrasound techniques, particularly ultrasound-stimulated microbubbles (USMB) and sonoporation, have been proven to transiently increase tumor membrane permeability, thereby enhancing the delivery of chemotherapeutic agents. These techniques generally utilize low-intensity focused ultrasound (LIFU) at frequencies of 0.5–3 MHz and intensities of 0.5–2 W/cm2 with microbubbles containing lipid or protein shells (1–10 μm in diameter) filled with perfluorocarbon gas designed to enhance cavitation effects.[2] In clinical and preclinical trials, USMB has been shown to enhance proapoptotic pathways and disrupt vascular endothelium, which leads to tumor cell death and better response to chemotherapy. A study reported that ultrasound-mediated delivery of gemcitabine for the treatment of pancreatic tumors in mice resulted in a statistically significant reduction in tumor size when compared with control and gemcitabine-alone groups. No significant toxic side effects were observed in treated mice, supporting the efficacy and safety of the procedure.[3] The clinical translation of these findings is rapidly advancing. A recent trial in advanced pancreatic cancer is examining sonoporation to increase chemotherapy uptake, using LIFU at 1 MHz and microbubbles with a mean diameter of 2–4 μm. Preliminary evidence favors improved drug delivery into tumor cells, whereas pharmacokinetic observations show manifold increases in intratumoral drug concentrations compared to systemic levels, thus reducing systemic toxicity.[4,5] This is achieved with a minimal side effect profile, as the ultrasound waves make the microbubbles oscillate, transiently opening cell membranes to enhance ingress. Recent studies have described objective response rates (ORR) of 35% for the USMB group compared to 15% in the control group when measured against conventional chemotherapy; however, these results are preliminary given the study sample size of 40.[6] For brain tumors, such as glioblastoma, LIFU facilitates repeated, noninvasive blood-brain barrier (BBB) opening for improved drug and biomarker delivery. In a phase 1/2 trial, 33 patients underwent 90 total sonications with carboplatin and demonstrated enhanced BBB permeability without dose-limiting toxicity; however, the small sample size limits definitive conclusions regarding efficacy, reinforcing the preliminary nature of these safety and feasibility findings.[7] The mechanisms of ultrasonic tumor permeabilization are multifaceted. The mechanical mechanisms of cavitation and sonoporation transiently disrupt the cell membranes, whereas ultrasound-responsive nanocarriers and microbubbles are used for on-demand localized drug release.[1] Immunotherapies can strengthen such effects: wearable flexible ultrasound microneedle patch (wf-UMP) studies have particularly shown immune pathway upregulation and enhanced antitumor immunity in combination with checkpoint inhibitors. Specifically, wf-UMP increases expression of PD-L1 and infiltration of CD8+ T cells, synergizing with anti–PD-1 antibodies to amplify tumor-specific immune responses.[8] The pharmacokinetic data also confirm lower systemic toxicity, with intratumoral drug concentrations several times higher than plasma levels, thereby mitigating off-target effects.[9] In brief, ultrasonic tumor permeabilization offers a promising future for chemotherapeutics in solid cancers by overcoming drug delivery barriers, thus augmenting efficacy while lowering systemic toxicity. Despite small sample sizes in earlier trials (e.g., n = 33 in glioblastoma trials) that preclude definitive efficacy claims, the abundant safety and feasibility data strongly support further research efforts.[10] As evidence from recent trials accumulates, there are compelling reasons to support oncological protocols that integrate this technology and expand its applications to additional malignancies. A multidisciplinary approach and robust regulatory framework will pave the way for safe, equitable, and swift clinical implementation of this promising technology.